A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022 the use ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Number 5: Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like ...

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its ...

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions ...